Objective To analyze the global research status,hotspots,and frontiers of proprotein convertase subtilisin/Kexin type 9(PCSK9)monoclonal antibodies,and to provide a reference for related scientific research and the rational drug use in clinical practice in China.Methods The research literature related to PCSK9 monoclonal antibody included in the Web of Science database was searched for the period from January 2011 to February 2022,and the literature included in the study was visually analyzed by the CiteSpace software.Results A total of 723 articles were included,and the annual number of publica-tions showed an overall upward trend.The top three countries were the United States,France,and the United Kingdom.Sanofi was the organization with the largest number of articles,and the organization with the highest citation of articles was Brigham and Women's Hospital.The hotspots of research mainly included the use of PCSK9 monoclonal antibody in the treatment of patients with hypercholesterolemia,patients who do not tolerate statins,patients with high cardiovascular risk,and the efficacy and safety of PCSK9 monoclonal antibody in lipid-lowering therapy combined statins;The frontiers of research in recent two years is the appli-cation of PCSK9 monoclonal antibodies in patients with acute coronary syndrome and the clinical benefits after reducing the level of lipoprotein(a).Conclusion A large number of studies have confirmed the efficacy and safety of PCSK9 monoclonal anti-bodies in reducing blood lipids,but there is still a lack of research on its economics and application in special populations,which should be the focus of future research.

Objective:To compare the clinical efficacies of arthroscopic acromioplasty combined with platelet-rich plasma (PRP) and acromioplasty alone in the treatment of subacromial impingement syndrome (SAIS).Methods:A retrospective cohort study was conducted to analyze the clinical data of 30 patients with SAIS. The patients, who were admitted to the General Hospital of Chinese PLA Eastern Theater Command from January 2020 to December 2021, included 9 males and 21 females, with the age range of 24-48 years [(34.3±9.8)years]. There were 19 left shoulders and 11 right shoulders. All the patients underwent arthroscopic acromioplasty. A total of 15 patients were injected with 4 ml of PRP after surgery (acromioplasty+PRP group), while the remaining 15 patients received nothing (acromioplasty group). Visual analogue score (VAS), Constant-Murley score, and active forward flexion, abduction, internal rotation, and external rotation of the shoulder joint were compared between the two groups before and at 6 weeks, 3 months after surgery and at the last follow-up. The postoperative complications were also observed.Results:All the patients were followed up for 3-12 months [(9.0±2.6)months]. There was no significant difference in VAS or Constant-Murley score between the two groups before surgery, at 3 months after surgery, and at the last follow-up (all P>0.05). At 6 weeks after surgery, the VAS and Constant-Murley score were (1.5±0.5)points and (80.3±6.2)points in the acromioplasty+PRP group, which was lower or higher than those in the acromioplasty group [(2.5±0.7)points, (58.1±7.6)points] ( P<0.05 or 0.01). The VAS showed gradual decrease and the Constant-Murley score showed gradual increase in both groups after surgery ( P<0.05 or 0.01). There were no significant differences in active forward flexion, abduction, or internal rotation of the shoulder joint between the two groups before surgery, at 3 months after surgery, and at the last follow-up (all P>0.05). At 6 weeks after surgery, the active forward flexion, abduction and internal rotation of the shoulder joint were (158.1±26.3)°, (146.2±27.4)° and (54.2±11.8)° in the acromioplasty+PRP group, respectively, which were significantly larger than those in the acromioplasty group [(128.8±29.6)°, (111.0±28.6)°, (35.7±12.3)°] ( P<0.05 or 0.01). The active forward flexion, abduction and rotation of the shoulder joint were gradually improved in both groups after surgery ( P<0.05 or 0.01). There was no significant difference in the active external rotation of the shoulder joint between the two groups at different time points (all P>0.05). No complications such as infection or acromion fracture appeared in the acromioplasty+PRP group; only one patient in the acromioplasty group had delayed wound healing, which was healed by dressing change. Conclusion:Compared with acromioplasty alone, acromioplasty combined with PRP can alleviate pain at early stage, promote shoulder function recovery, improve joint active range of motion, and reduce the incidence of acromioplasty.